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ABSTRACT
There is increasing concern globally about the enormity
of the threats posed by antimicrobial resistance (AMR)
to human, animal, plant and environmental health. A
proliferation of international, national and institutional
reports on the problems posed by AMR and the need
for antibiotic stewardship have galvanised attention
on the global stage. However, the AMR community
increasingly laments a lack of action, often identified as
an ‘implementation gap’. At a policy level, the design of
internationally salient solutions that are able to address
AMR’s interconnected biological and social (historical,
political, economic and cultural) dimensions is not
straightforward. This multidisciplinary paper responds by
asking two basic questions: (A) Is a universal approach to
AMR policy and antibiotic stewardship possible? (B) If yes,
what hallmarks characterise ‘good’ antibiotic policy? Our
multistage analysis revealed four central challenges facing
current international antibiotic policy: metrics, prioritisation,
implementation and inequality. In response to this
diagnosis, we propose three hallmarks that can support
robust international antibiotic policy. Emerging hallmarks
for good antibiotic policies are: Structural, Equitable and
Tracked. We describe these hallmarks and propose their
consideration should aid the design and evaluation of
international antibiotic policies with maximal benefit at
both local and international scales.

INTRODUCTION: ANTIMICROBIAL RESISTANCE AS
A BIOSOCIAL PROBLEM
Since their introduction in the 1930s, antibiotics have acquired infrastructural importance in global health and food production.1 However, antibiotic reliance comes
with a trade-off: using antibiotics accelerates
the emergence of antimicrobial resistance
(AMR), which diminishes their future effectiveness. This makes effective antibiotics a
precious ‘global common-
pool resource’,2–6

Summary box
►► The global crisis of antimicrobial resistance has led

to a proliferation of expert reports and national and
international antibiotic action plans.
►► Implementing international antibiotic policy that is
meaningful in different social, cultural and economic
contexts continues to prove challenging.
►► Our multidisciplinary analysis has identified four
critical challenges of metrics, prioritisation, implementation and inequality for international antibiotic
policy-making.
►► We propose a corresponding SET of basic hallmarks of good antibiotic policy, which we define as
Structural, Equitable and Tracked.
►► Our SET of hallmarks can orientate disciplinary debates and provide a framework for developing robust
international interventions.

which can benefit humanity but will provide
diminishing benefits if we fail to coordinate plans for preservation (a tragedy of the
commons).
Over the past decade, rising concern
about AMR has highlighted the need for
collective action to protect our antibiotic
‘commons’.2 7–12 Governmental and non-
governmental organisations have devoted
substantial resources to tackling AMR and
preserving antibiotic effectiveness on national
and international stages.13 Increasing attention and funding have been accompanied
by a proliferation of expert reports and
policy proposals.14 While these AMR-focused
initiatives have succeeded in achieving a
clear international consensus on the need
for action, many lament a lack of action in
practice, dubbed an ‘implementation gap’.
Substantial uncertainties also remain about
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Setting the standard: multidisciplinary
hallmarks for structural, equitable and
tracked antibiotic policy
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THE FOUR CENTRAL CHALLENGES OF ANTIBIOTIC REGULATION
Metrics
Despite long-standing regulation attempts, there remains
substantial uncertainty about basic metrics surrounding
antibiotic usage and AMR as well as about how to correlate measurements in a way that can inform meaningful
2

Box 1 Three stage evidence gathering, evaluation and
consultation process
Stage 1:
Following a 2018 Social Science and antimicrobial resistance
(AMR) Research Symposium at the British Academy in London,162 a
correspondence group of fourteen experts from the humanities, social,
environmental and medical sciences reflected on whether there could
be universal principles of international antibiotic policy making and
hallmarks of ‘good’ policy.

Stage 2:
Identified policy challenges and core hallmarks of successful
intervention informed a preliminary paper, which was circulated
among correspondents and attendees of a multidisciplinary 2-day
workshop in London in March 2019.
During presentations, small group breakout sessions, and group
discussions, participants reflected on the preliminary paper’s four
identified problem areas for antibiotic regulation: (A) metrics (defining
and measuring AMR, antibiotic usage and performance indicators for
interventions); (B) prioritisation (prioritising specific forms of antibiotic
use over others); (C) implementation (developing and implementing
interventions that are meaningful in high-income, medium-income
and low-income settings); (D) inequality (formulating interventions
that take into account global disparities of wealth, infectious disease
and AMR burdens and access to antibiotics as well as effective health,
water, sanitation and hygiene systems).
There was agreement on these interlinked problems but the
four provisional hallmarks proved more contentious: (1) antibiotic
policymaking should take into account antibiotics’ infrastructural
relevance in medicine and food production; (2) should increase the
microbial resilience of health and food systems to diminish the need
for antibiotics; (3) be responsive to evolving knowledge regarding AMR
and (4) relational in its acknowledgement of differing local challenges
and capacities.
Participants agreed that there was no single solution to AMR but
felt that hallmarks needed to be integrated and go beyond preserving
the status quo. Key to more effective policymaking has to be an
acknowledgement of antibiotics’ primary utility for global health and
food production, which consists in their ability to reduce mortality
and morbidity resulting from treatable infections. To preserve this
utility, the overriding aim of any antibiotic policy must therefore be
(1) to maximise and maintain access to effective treatments for
infections, which includes the development of new treatments—while
(2) reducing the need for antibiotic use by preventing infections,
reducing antibiotic dependencies in healthcare and food systems,
and minimising the environmental load of antibiotics and resistant
bacteria.

Stage 3:
A refined version of new Structural, Equitable, Tracked Hallmarks was
circulated among correspondents and participants, who were invited
to be coauthors on the paper.

policy formulation at the national and international
levels.22
How to define resistance?
Since the first warnings about ‘drug fastness’ in microorganisms in 1907,23 24 there has been no clear transdisciplinary or international consensus on how to define
AMR. The constantly evolving nature of AMR, the
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the effects of different policy interventions, how international policies could be enforced globally, and who will
pay in the long term. The main difficulty with managing
the antibiotic commons seems to lie in jointly addressing
the complex biological and social (understood here to
be historical, political, economic and cultural) dimensions of AMR. Policy formation for the latter dimension
is particularly challenging because it entails addressing
different metrics, meanings and challenges in different
settings.
angle approach to AMR-
We propose a new wide-
focused antibiotic regulation. Two basic questions guide
our reflective process: (A) Is a universal approach to
AMR policy and antibiotic stewardship possible? (B) If
yes, what hallmarks characterise ‘good’ antibiotic policy?
To answer these questions, we have developed an innovative heuristic evaluation framework, which accounts
both for AMR’s biological and social facets. Our approach
was informed by the numerous national and international reports proposing various principles for antibiotic
policy-making2 10 11 15–17 and the historical success of the
3Rs (Reduction, Refinement and Replacement) that
restructured laboratory animal testing protocols. Developed as principles of ‘good animal experimentation’ in
1959, the 3Rs were concrete and aspirational enough to
trigger a progressive evolution of protocols and dialogue
in a contested policy arena.18(So et al have proposed
three Rs for antimicrobial development).19
Applying this approach to AMR and antibiotic policy,
our collaborative multidisciplinary analysis employed a
three-stage evidence gathering, evaluation and consultation process (box 1), which consisted of: (1) asking
selected medical humanities and sciences researchers
whether they believe antibiotic policies could feasibly
be guided by a universal set of guiding principles, and
what they consider those guiding principles could be;
(2) identifying possible hallmarks of good policy with a
broad group of stakeholders from academia, medicine,
animal/plant production, policy and funding bodies at
an international workshop and (3) refining identified
hallmarks in light of multidisciplinary feedback.
We believe that the resulting heuristic compass based
first on the identification of central challenges of antibiotic policy-making (metrics, prioritisation, implementation, inequality) and second on the formulation of a
corresponding Structural, Equitable and Tracked (SET)
of hallmarks of good antibiotic policy, which we define
as SET can orientate disciplinary debates and provide a
framework for robust international interventions.10 20 21
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Whose methods count?
Internationally, the establishment of WHONET (est.
1989) and WHO’s Global Antimicrobial Resistance
Surveillance System (GLASS, est. 2015) marked important efforts to standardise AMR reporting in humans
and make data comparable.28 29 However, coordination problems remain: testing protocols by influential
bodies like the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) and the US-based Clinical Laboratory Standards Institute (CLSI) occasionally
diverge. Resulting international monitoring differences
are exacerbated by issues of access (see problem area
Inequality).30 EUCAST guidelines and updates are available free of charge. By contrast, CLSI guidelines and
updates are often pay for use, which makes it difficult for
resource poor laboratories to keep protocols up to date
and feedback local AMR data into international databases.31 In low and middle income countries (LMICs),
surveillance is often further complicated by lack of access
to laboratory equipment, service contracts and paywalled
literature.32 Ensuing disparities in global AMR reporting
mean that international reports disproportionately reflect
data from resource-rich settings and a limited number of
well-studied low-income sentinel sites with international
healthcare infrastructure investment.33 Resulting international stewardship and policy guidelines may, however,
be of limited use in understudied resource-poor settings
with different AMR ecologies and no access to key antibiotics.
What is relevant antibiotic use data for AMR?
Capturing relevant data on antibiotic use to inform
AMR efforts has its own challenges. Starting in the
1990s, various high income countries (HICs) began to
compile antibiotic usage data.34–37 However, data collection methods continue to vary. In the case of antibiotic
usage in animals, the World Organisation of Animal
Health (OIE) has begun to collect data on antibiotic
sales intended to be used in animals and usage data
since 2015. However, despite ongoing progress, data gaps

remain with almost 25% of 182 OIE Member Countries
not reporting quantitative and most reporting antibiotic
sales and imports data but no data on use for the fourth
OIE round of data collection.38 Reporting differences
are also common among HICs. The EU developed a
standardised metric to correlate antibiotic sales with the
volume of animal production (mg/population correction unit) from 2010 onwards.39 Individual EU countries
like Britain and Denmark publish not just sales but farm
usage and prescription data for certain livestock categories.40 41 By contrast, the US Food and Drug Administration (FDA) publishes sales data only in broad categories
of drug class by species but no usage data, which complicates AMR risk assessment.42
Correlating usage and AMR data is even more challenging. In its 2018–2019 report, the English Surveillance
Programme for Antimicrobial Utilisation and Resistance
(ESPAUR) showed a significant reduction in antibiotic
prescriptions but an increase in antimicrobial-resistant
infections for the seven priority bacterial pathogens
reported.43 In 2017 and 2019, longitudinal studies of
bloodstream infections in Malawi showed a long-term
reduction of overall infections but a rise of antibiotic
resistance in remaining infections.33 44 To be useful,
aggregated metrics of antibiotic usage (including class of
antibiotic) across infection types need to be contextualised with outcome and population health metrics, such as
infection, resistance and morbidity/mortality rates.45–47
Understanding what the implications of specific forms
of antibiotic usage (eg, prophylaxis, therapy, growth
promotion) in different environments are for AMR and
health outcomes is similarly crucial for policy formulation. Rising numbers of point prevalence studies and
whole-
genome sequencing are enhancing our knowledge of drivers and variations of AMR over time and in
different areas across the world.48–51 However, our wider
understanding of the evolutionary factors underlying
AMR levels is still fragmentary as is our understanding of
which stewardship interventions might make how much
of a difference: in some cases like targeted 1950s antibiotic prescription bans at St Bartholomew’s Hospital
in London52 or Denmark’s 1990s ban of lower-
dosed
avoparcin and tylosin animal growth promoters, reducing
selection pressure by a specific type of drug usage led to a
marked reduction, but not a complete disappearance, of
correlating AMR.53 54 In other cases, antibiotic reductions
may take years to manifest in terms of reduced AMR—as
highlighted by the UK’s 2019 ESPAUR report and experiences in Scandinavian countries.43 53 55 Finally, some
usage reductions may come too late to shift the evolutionary balance back in favour of microbial sensitivity as
occurred with China banning the use of colistin growth
promoters in 201656 following a report of the transferable
mobilisable colistin resistance MCR-1 gene.57 Subsequent
reports, however, showed that the gene was detectable in
strain collections from more than 30 countries and was
already circulating in Escherichia coli in China in the mid
1980s.58 The lack of uniformly comparable data makes
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introduction of new drugs and the different availability
and use of antibiotics means that terms like drug sensitive, intermediate resistant or resistant, mean different
things in different regional contexts. There is also no
transdisciplinary consensus on whether to define AMR
according to predefined clinical breakpoints, minimum
inhibitory concentrations, epidemiological cut-offs, pharmacokinectic/pharmacodynamic models, the presence
or absence of resistance-conferring genetic elements or
clinical impact on patients or animals. Disagreement over
this latter point is highlighted by the common absence
of drug-resistant infection as an official cause of death.
Historically, the lack of consensus over AMR has led to
differing microbiological and public health definitions
of AMR with the former measuring incremental changes
of microbial susceptibility and the latter measuring
instances of treatment failure at predefined dosages.25–27

BMJ Global Health

How to develop meaningful key performance indicators?
While uncertainty remains about the degree to which
interventions will be effective, reducing the overall
amount of antibiotics used in health and animal and plant
production systems is a key component of most AMR
action plans.11 13 59 Over the past two decades, international bodies have attempted to decide which antibiotics
to protect from overuse. Since 2004, WHO, OIE and the
Food and Agriculture Organization (FAO) have begun
using the categories of critically important antimicrobials
(CIAs), highly important antimicrobials and important
antimicrobials—although differences in the categorisation of the same drugs for veterinary and medical usages
can remain.60 61 In 2019, the WHO’s Essential Medicines
List added the AWaRe categorisation, to meet a need
to recognise those medicines that should be Accessed as
first-line narrow-spectrum treatment for particular conditions, and those with higher risks of becoming resistant
that should be used Watchfully and those that should be
Reserved for last-line treatment.62 This framework can
be used as an index—the ratio of Access to Watch and
Reserve medicines—to compare prescribing practices in
different contexts, which goes some way to balancing the
different challenges of improving access and restricting
excess when setting targets.63 However, measurement of
antibiotic usage remains a challenge. Although WHO and
OIE have standardised methodologies to collect country-
level antimicrobial usage in humans and animals for
global reporting and consulting companies like IQVIA
gather and sell additional proprietary data,64 65 more
granular level detail about antibiotic usage on farms and
in particular clinical and residential settings is required
for targeted reduction strategies.66 67
Alongside improved usage data, deciding which
microbes, resistance genes and AMR reservoirs to
monitor in medical, animal and plant production, and
environmental settings is similarly important for the
formulation of meaningful policy interventions. For
humans, WHO published a list of priority pathogens to
monitor and target with antibiotic development efforts in
2017.68 For animals, the OIE Member Countries agreed
on harmonised lists for both terrestrial and aquatic
animals.69 70 However, it remains difficult to prioritise
which sentinel organisms to survey and where potentially
important AMR reservoirs are located due to different
health threats in HICs, MICs and LICs, lacking clinical
surveillance infrastructure in many LMICs and of environmental surveillance in the most countries, regionally
skewed reporting that often centres on urban clinical
settings, and limited diagnostic capabilities for non-classic
pathogens.71 72 Furthermore, particular microbes such as
Staphylococcus aureus and E. coli may or may not be causing
disease, and therefore, their measurement without corresponding disease burden data might be misleading.
4

Discussed in more detail below (see Tracked), one
recently proposed solution for human health might be
to integrate AMR and infection burden measurements
by tracking two priority organisms in bloodstream infections as part of United Nations (UN) Sustainable Development Goal (SDG) 3.d.1. This new AMR-specific SDG
could help build laboratory capacity in resource-
poor
settings and spur the development of further integrated
AMR-
specific metrics. Another approach might be to
strengthen point prevalence studies for specific sentinel
organisms in LMIC settings.73 (Consultations on sentinel
organisms and sentinel sites are ongoing by GLASS and
the point prevalence survey).
The described temporal and contextual challenges of
defining resistance, measuring antibiotic usage in relation to AMR and concerning which microbes to focus on
also raise important questions when it comes to defining
benchmarks or key performance indicators (KPIs) for
policy initiatives: how far should antibiotic sensitivity
be restored or preserved for a measure to be considered successful? Should the performance of a policy be
linked to its reduction of antibiotic usage or should the
KPI be demonstrated impact on human health? Should
success be defined as the stabilisation or decline of AMR
in specific culturable pathogens? Given the mobility of
resistance genes and the One Health dimensions, should
a metric of success be the abundance or prevalence of
a particular resistance gene in the wider environment,
determined through quantitative PCR methods74? How
much time should policies have to achieve their goals?
Prioritisation
Overemphasis on surveillance data itself can serve to
obscure different regional capabilities, underlying political interests and competing needs in animal and human
medicine.75 In addition to defining meaningful metrics, a
significant challenge facing international antibiotic regulation is which form of antibiotic use to prioritise in the
face of time-limited microbial sensitivity to most drugs
and heterogeneous epidemiological, social, economic
and material contexts. The challenge of prioritisation
comprises spatial and temporal components.
Spatial: since the 1940s, regulators have tried to protect
important antibiotics by restricting their use,76 but this
path-dependent prioritisation has been enacted differently across varying local, regional and national settings.
Antibiotics’ infrastructural importance in global healthcare and food production means that a large number of
sectors with different needs depend on routine antibiotic access.1 In the case of Europe and North America,
historians have shown that distinct national antibiotic
usage patterns have become socially entrenched over
decades.77–81 To this day, antibiotic usage patterns vary
across Europe and North America despite both regions'
close economic, political and cultural ties.82 83 Differences of usage are even more substantial between HICs
and LMICs with patients in the latter countries often
depending to a much stronger degree on the efficacy
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it more difficult to evaluate trade-offs in various policy
options.

BMJ Global Health
underlying drivers of infection in human, animal health
and plant production systems. The tendency to see antibiotics as ‘quick fixes’ has helped drive AMR and often
distracted from investment in more sustainable forms of
infection prevention like effective and affordable health,
Water, Sanitation and Hygiene (WASH), and Infection
Prevention Control (IPC) systems (see also Inequality
below).85 Over-reliance on antibiotics has also been exacerbated by industry marketing of, in part, inappropriate
antibiotic usage and targeted campaigning to undermine usage restrictions in high-income and low-income
settings.34 77 107
Implementation
A third fundamental challenge for antibiotic policy-
making concerns the formulation of binding international agreements that can still be implemented flexibly
in different settings.17 108 Recent international agreements like the 2016 UN Paris Agreement on climate
change remain based on the classic so-called Westphalian
model of sovereign nation-states agreeing on a set of
measures, which are then independently enacted within
their borders without control by other actors.7 12 109 110
There are a number of challenges with this model: global
trade flows are not easily regulated by nation-level policies; with few exceptions like the International Health
Regulations on pandemics, international organisations
like the WHO cannot enforce health agreements negotiated under their umbrella; the ability of governments
to implement policies varies.8 20 110 111 Described implementation problems are exacerbated by the widespread
absence of basic data and robust metrics (see above) to
inform international policymaking. For example, while it
may seem straightforward to define and evaluate policy
success as reductions of drug usage in HICs, these metrics
will likely fail in settings without reliable consumption/
usage data and where informal grey market and unregulated over-the-counter sales account for a large part of
the antibiotic supply.82 112 113
Using an integrated political, economic, sociological, technological, ecological, legislative and industry
framework, reviews of national action plans proposed
after the 2015 Global Action Plan on Antimicrobial
Resistance have warned of continuing gaps in applying
international concepts of stewardship at the national
level.114 115 Focusing only on international and not on
actual local policy alignment can foster the creation
of ‘paper tiger’ initiatives, which are not enforced—as
in the case of enacted but not enforced bans of over-
the-
counter antibiotic sales116—or obscure or relabel
existing practices rather than reform underlying antibiotic infrastructures.13 117 118 Follow-up reports by WHO,
UN and World Bank have proposed solutions including
international investment in local IPC, antibiotic quality
assurance and access schemes, AMR surveillance, vaccination, local stewardship champions and contextualised
policy-making.10 20 21 111 In the case of animal production,
experts have proposed using AMR monitoring in sentinel
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of a limited number of locally available, affordable and
easily administrable drugs—particularly in areas where
there is no access to professional healthcare facilities.84–86
If different countries, sectors and even local healthcare
facilities87 use different antibiotics for a variety of biological and social reasons, whose form of antibiotic use
should receive priority?
The same problems of spatial prioritisation hold true
in animal and plant production.34 88 One example of
spatialised inequality of access are the polymyxin antibiotics (eg, colistin, discovered in 1949). After using the
drugs to treat gram-negative infections in humans, HICs
greatly reduced use of polymyxins in favour of less toxic
carbapenems from 1980 onwards.89 Although limited use
of ‘old’ colistin continued in HICs, their low cost and
lacking HIC demand for human medicine led to aggressive pharmaceutical marketing and large-
scale uptake
for growth promotion and disease prevention in the
industrialising animal production of LMICs like China
and Brazil.88 When rising carbapenem resistance led to a
resurgence of polymyxin use in human medicine around
2005, competing animal production and medical priorities meant that global regulators did not raise polymyxins’
status to that of CIAs. It was only after the discovery of the
mcr-1 gene on transferable plasmids in bacterial isolates
from Chinese pigs that polymyxins were recategorised as
highest priority CIAs in 2016, received specific restriction
recommendations from OIE, and were banned from use
as growth promoters in China and Brazil.57 60 75
Temporal: another challenge of prioritisation regards
the inevitable temporal conflict between acute healthcare needs and the future-focused dimensions of antibiotic stewardship.90 There is a well-
evidenced ethical
dilemma between preserving drugs’ future efficacy and
using antibiotics to safe-guard vulnerable populations in
the present. This is highlighted by studies on the rise of
multidrug-resistant pathogens in itinerant and immunocompromised HIC and MIC populations91–94 or of AMR
proliferation as a result of high levels of antibiotic use
in prolonged crisis situations like the 2009 H1N1 influenza or the current COVID-19 pandemic.95–98 Similar
dilemmas have also become apparent in campaigns of
antimicrobial mass drug administration to prevent child
stunting,99 100 against onchocerciasis, lymphatic filariasis
or malaria,101 in the mass administration of azithromycin
against drivers of childhood mortality in Tanzania, Niger
and Malawi,102 103 and to prevent scabies and impetigo on
the Solomon Islands.104
Answers to this temporal dilemma vary and reflect
the perceived severity of need, cultural preferences for
specific forms of use, and economic considerations. In
some cases, the potential longer-term risk to public health
of antibiotic resistance has been favoured over immediate
clinical needs.105 However, in the main, present needs
have overridden future-
focused stewardship concerns.
While there is no reason not to use antibiotics to save
and improve lives, they have often been used as a ‘quick
fix’106 to symptomatically control rather than eliminate
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Inequality
One of the most significant challenges facing international antibiotic policy and global health frameworks
more widely are significant levels of inequality between
and within HICs and LMICs. These inequalities reflect
historically uneven social and political opportunity as
well as distribution of economic resources and disease
burdens. Inequality has large implications for ways priorities are made and implemented in relation to antibiotics. Recognition of these inequalities challenges forms
of policymaking that focus on metrics of drug reduction
alone (see Metrics and Implementation above) or prioritise protection of HIC hospital antibiotics over LMIC
needs for access to antibiotics and protein production.
The unevenness of social and political opportunities
affects who can make or demand policies. At the international level, the historical dominance of HICs on relevant
health bodies and many funders’ and high-level meetings’
location in HICs has led to a relative absence of the voices
of some of the most affected LMIC stakeholders.124 There
is a historically evidenced danger that this dominance of
HIC voices can drown out LMIC concerns and lead to
narrow policies centring on HIC concerns.125 126 Despite
best intentions, motivations for international antibiotic
policy initiatives must thus be considered uneven when
framed with a health security lens—who is the ‘we’ in the
need to act, and who is the ‘us’ being protected1?
6

Answering these questions is important. In the case of
drug development, historical priority setting has been
centric due to the greater profitability of high-
HIC-
income markets (with a particular emphasis on the most
lucrative US market) and differing regional risk priorities.111 127 In the case of surveillance, antibiotic resistance
and usage indicators emerge unevenly from particular
locations, prioritise particular security concerns and
carry particular interpretations. When shuttling between
different contexts in which resistance and use might have
a different significance, these abstracted numeric indicators can foster a contextual disconnect among decision-
makers.128 The described surveillance disconnect is
exacerbated by the relative lack of data from LICs and
rural settings (see Metrics above). The result is a vicious
circle: lacking access to equipment, current standards and
scholarly literature means that disease and AMR burdens
cannot be measured and published,32 which means that
there are no data with which to build local expert capacity
or inform international policy, which compounds the
obscuring of difference between contexts.
Over time, decontextualised international decision
making can result in policies that prioritise HIC-centric
stewardship interventions like targeted drug restrictions
that may prove deleterious in LMICs where infection
risks are markedly higher and different.111 129 Limited
data indicate an inverse correlation between countries'
gross national income and invasive infections caused by
WHO top-ranked antibiotic-resistant bacteria.71 Where
resources are stretched thinly across health systems and
infrastructure, other priorities than stewardship may
be more pressing for investment. For example, IPC in
health facilities and availability of effective WASH systems
are essential. However, in 2017, ca. 785 million people
worldwide had no access to safe drinking water, two of
every seven people had no access to sanitation, and 22%
of LIC health facilities had no water service.130 131 Indeed,
investment in IPC and WASH is likely to be most effective
for reducing AMR in many settings as a base on which
stewardship might then be built.10 20 132 Furthermore, in
many settings the ability to provide equitable access to
essential medicines of sufficient quality, including antibiotics, remains elusive.10 112
Similar constraints are true for animal health which
is related to issues such as food safety, food security and
animal welfare. Many national and international action
plans invoke enhanced biosecurity facilities, vaccination or good husbandry practices as a means to avoid
unnecessary non-human antibiotic use, but they rarely
set these measures as (funded) priorities contrary to
raising awareness, developing surveillance or promoting
responsible and prudent use, or they risk assuming inappropriate livestock production and disease management
approaches in settings where economic and microbiological risks are manifestly different.133–135 While arguments
for wider systems strengthening should not undermine
statutory antibiotic reform, decontextualised policies
focusing only on antibiotic stewardship and surveillance
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pathogens and technical support from HICs as tools to
incentivise global reductions of antibiotic usage.119 Promising access to lucrative markets and using transnational
integration to promote precautionary antibiotic policies
is an additional tool that was used by the UK in the 1970s,
Sweden in the 1990s, and is now being considered by the
EU to reduce antibiotic growth promoter and prophylactic antibiotic use in non-European countries.34 120
However, so far, enactment of proposed measures
has been fragmentary13 and it remains unclear how
numerous national and international calls to action with
complex interlayered principles of action can be translated into effective change in settings where antibiotic
access is lacking and AMR is secondary (at best) to other
health concerns. Looking beyond top-down nationstate
alignment, by reemphasising municipal and community-
based health initiatives as well as creating new metrics for
antibiotic access before prioritising stewardship may be a
solution. Recent social sciences research suggests the efficacy of adaptive value-driven bottom-up reforms. These
reforms move from merely sanctioning inappropriate
antibiotic use to identifying the sociostructural factors
driving antibiotic use and devising targeted incentives
for locally tailored shifts to more appropriate antibiotic
use.121–123 However, it remains unclear whether relying
on local or even regional solutions will be able to solve
the global challenge posed by AMR. Calls for behavioural
change, industry reform and individualised policymaking
have often been ineffective.34 77
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Interlinked hallmarks of successful antibiotic policy-making.

risk distracting from the even more important structural
absence of adequate and situationally appropriate sanitary, veterinary and healthcare systems in many parts of
the world.
HALLMARKS OF GOOD ANTIBIOTIC POLICY
The four biosocial challenges of metrics, prioritisation, implementation and inequality require a holistic
response from international antibiotic policy that is ambitious enough to improve the status quo but concrete and
evocative enough to be an effective guide. Because such
policies are enacted within a complex ecosystem, a broad
perspective needs to inform their design and deployment
to maximise effectiveness and minimise unintended
consequences. It is this broad heuristic perspective,
incorporating One Health, spatial, temporal and ethical
dimensions that underlies the three interlinked SET hallmarks proposed here (figure 1).
1. Structural: International antibiotic policies should
recognise and respond to the multiple aspects of global antibiotic infrastructures.1 Since the 1930s, antibiotics have replaced older, more expensive forms of infection control in humans, animals and plants and enabled new medical interventions like organ transplants
and prosthetic joint implants. Global health and food
production systems rely on the comparatively cheap
‘work’ performed by antibiotics. Reforming antibiotic
use cannot be separated from broader reforms of the
infrastructures that have evolved around them.
Historically, there has been a tendency to make AMR
manageable by compartmentalising problems and
blaming individuals for drug overuse instead of the
underlying social, political and economic factors driving antibiotic demand and dependencies (see Metrics
Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091

and Prioritisation).34 77 136 137 In HICs, a long-standing
focus on technical quick fixes and individual behavioural change meant that farmers and patients were
routinely blamed for overuse without targeting wider
infrastructural factors or the companies and experts
supplying antibiotics.106 Bureaucratic divisions also
meant that the same antibiotics could be subject to
different regulations on farms and in clinics (see Implementation). The fact that most reforms stopped
at national borders further fragmented international
regulation.76 88 136 Since the adoption of One Health
terminology by WHO and EU antibiotic regulators
around 2010,138 nearly all international AMR initiatives have attempted to overcome described problems
by integrating polices for drug regulation in human
medicine, animal production and the environment.
However, beyond surveillance, One Health was initially often narrowly applied to mean ‘animals’ rather than the wider environment—perhaps reflecting
the absence of the UN Environmental Programme
from the original Tripartite coalition of FAO, OIE and
WHO. Recent European, Indian and private initiatives now explicitly target wastewaters and industrial
wastes15 134 139 140 but implementing new standards remains challenging. Meanwhile, our scientific understanding of the relative effect of antibiotics, metals and
biocides on environmental AMR burdens and of the
efficacy of proposed interventions remains fragmentary.74 141 142
Successful antibiotic stewardship cannot be narrow
and divorced from the social and environmental contexts in which use is taking place. More effective international policy requires the abandonment of regulatory silos, as well as the adoption of context-sensitive
7
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profited from early antibiotic sales. HICs’ historical
contribution to current AMR levels and role in spreading antibiotic dependent infrastructures to other parts
of the world88 148 entail a moral obligation to bear a
higher burden when it comes to mitigating resulting
problems.110 Similarly, recent and projected high levels of antibiotic use and production in MICs create a
comparable obligation to contribute resources to mitigate problems in poorer areas of the world and for
future generations.48 119 149 150
Whether action is justified on the basis of historical
usage, collective responsibility, obligations towards
future generations, or enlightened self-interest, any
international policy framework will have to include
long-term financial and political HIC and MIC commitments to support antibiotic sensitive interventions
in resource-poor communities. In LICs, antibiotic sensitive international support could centre on building
human and infrastructural capacity by educating and
employing more medical and veterinary professionals,20 enhancing laboratory provision and expanding
access to effective, affordable, and safe vaccines, antibiotics, and WASH and health systems. From a One
Health perspective, international policies should also
promote economically and environmentally sustainable forms of animal and plant production as well as
improve the management of waste containing antibiotics.
Well-designed structural and equitable international
antibiotic policies can generate a global win-win.110
Building LMIC capacity for disease control and prevention and providing equitable access to effective
treatments via market reforms, subsidies or public research and development127 151 152 will lower both local
disease burdens and rising international AMR-related
healthcare costs.10 20 111 127 In the case of animal and
plant production, equitable policies will recognise that
to ensure regional food security, targets for a sustainable antibiotic-controlled production system can only
come after an infrastructural groundwork is in place
to reduce reliance on these substances.119 123
Because of its structural dimensions, the lack of an easy
target and a dysfunctional commercial research and
development pipeline for new antibiotics,127 147 AMR
has so far failed to attract the same degree of resources that organisations like the Global Vaccine Alliance
(GAVI) (est. 2000) or the Global Fund (2002) have
mobilised for individual diseases like HIV/AIDS, tuberculosis, malaria or polio. Achieving truly structural
and equitable global AMR solutions will depend on the
more effective generation and pooling of investment
in safe antibiotic access, coordination of country-level
policy responses and provision of effective WASH,
IPC and educational resources.127 This role could be
fulfilled by the existing Tripartite and a One Health
Global Leadership Group on AMR.153 Another option
suggested by some authors is creating a new dedicated international AMR body or pooled fund similar to
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models. It requires a broad structural approach to
reforming not only the international antibiotic supply
chain (drug producers) but also wider contributing
global and regional consumption patterns (eg, rising
global demand for protein) as well as associated socio-
structural factors (eg, fractured health and WASH infrastructures, time constraints on diagnosis, profit incentives to prescribe or sell drugs) and environmental
factors (eg, infection burdens, drug residues in water
systems).
As evidenced by recent successes in HIC animal production and health systems, jointly focusing on preventing disease with vaccines and improved welfare,
updating the design of surveillance, hospital, animal
housing systems and modifying antibiotic-seeking behaviour by patients and animal and plant producers
can reduce antibiotic dependencies.143–145 However,
high-income infrastructural starting points cannot be
taken for granted elsewhere in the globe (see the Inequality section). To be effective internationally, the
nature of ‘intervention’ must be less ‘AMR-specific’
and instead build up ‘AMR-sensitive’ changes20 which
support wider UN SDGs including improved WASH,
nutrition and access to affordable medical and veterinary healthcare.10 20 While we do not discount the
importance of traditional regulatory tools like actively
enforced bans of over-the-counter sales, understanding the work that antibiotics perform in non-HIC settings may also lead to an interlayering of old and new
policy tools such as subsidised assurance and disease
insurance schemes for farmers phasing out antibiotics,
access to high-income markets for animal and plant
products produced without antibiotics, public antibiotic production or certified antibiotic distribution
schemes.20 127 146 147
2. Equitable: To be impactful globally, international
antibiotic policies must recognise and respond to the
unevenness in contributions towards and ability to
tackle AMR while aiming for an equitable future for
antibiotics regardless of where they are deployed. Historically, inequality and the difficulty of uniform policy implementation across HICs and LMICs have been
major obstacles for international antibiotic reform
(see the Inequality and Metrics section).
Because antibiotic effectiveness is a time-limited global common pool resource and even robust national
responses offer little protection from the global circulation of AMR genes and organisms, the sustained
pooling of international resources is an essential prerequisite to overcome identified challenges. Similar to
climate change, some countries have a greater differentiated responsibility to contribute resources to this
common pool than others.110 For decades, populations in HICs have had greater access to the antimicrobial commons than their counterparts in LMICs. High
volumes of HIC usage facilitated the historical selection for and global circulation of resistant genes and
organisms while HIC companies disproportionately
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Multifactorial
Achieving effective tracked interventions requires a
unifying global set of multifactorial metrics. To enable
the rigorous evaluation of policies, multifactorial
metrics need to simultaneously take into account antibiotic access, AMR and stewardship, but avoid rewarding
short-
termist gaming such as relabelling disease definitions, disincentivising healthcare-
seeking behaviour
and decontextualising surveillance (see the Inequality
section).128 154 Standardised terminology and transparent
AMR and drug usage surveillance are essential prerequisites for the design of meaningful international interventions. However, focusing too narrowly on reducing
drug usage and misuse will not curb microbial threats
(see Implementation section). Vice versa, focusing only
on providing drugs without supporting additional means
to reduce disease burdens will achieve little in the long
term. Since 2018, several ways have been proposed to
integrate AMR into the UN SDG framework. The most
recent proposal is to ‘reduce the percentage of bloodstream infections due to selected antimicrobial resistant
organisms’ and has been recommended to go forward
to the UN Statistical Commission for inclusion in SDG 3
(Good Health and Well-being).73 This is one promising
way to address stewardship without detracting from the
goals of antibiotic access and disease prevention (see the
Metrics section). There is, however, an additional need
for new multifactorial metrics that also encompass AMR’s
environmental and animal health dimensions as well as
local access to drugs, WASH, vaccines and coselection for
resistance by other antimicrobial substances. The new
monitoring and evaluation framework proposed by FAO,

OIE and WHO in 2019 is an important step in this direction.155
Integrated
In addition to drawing on multifactorial metrics, policy
tracking should aim to integrate metrics across domains:
taking into account the legacies of pre-
existing interventions, improving knowledge integration across One
Health sectors and incorporating knowledge generated
in other geographical and social contexts. Enhancing
the integration of international knowledge gathering will
strengthen regionally nuanced decision making. Since
the 1940s, successive generations of regulators have
tried to manage the antibiotic commons by focusing on
one form of intervention like ‘rational’ antibiotic use,
reducing antibiotic use via statutory bans or non-statutory
incentives and replacing antibiotics (eg, using metals in
animal feeds). However, lack of cross-sectoral and international integration meant that benefits were often
short-lived and had little effect on global drug usage or
AMR.34 76 137 156 157 Regulatory silos at the national and
international level have also repeatedly impeded the
transmission of knowledge generated in one sector to
other sectors—something that is exacerbated by the fact
that animal health, medical and environmental regulators rarely interact on equal terms.158–160 In the case of
AMR, the result was a lack of long-term strategic planning, a fragmentation of international policies and basic
metrics (see the Metrics section)—and a tendency to
reinvent the wheel—for example, the almost decennial
recurrence of official warnings about post-
antibiotic
futures and ‘rational’ antibiotic use campaigns.77 161
Developing equitable structural policy frameworks thus
not only depends on evaluating progress with multifactorial metrics but also on actively integrating knowledge
throughout the One Health domains, leveraging existing
national and regional policy frameworks and retaining
institutional knowledge.
Empowering
Developing multifactorial and integrated metrics will
achieve little if global AMR and usage data continues
to be generated and made available unevenly. Equitably
boosting laboratory and data analysis capacity is a prerequisite for strengthening the ability of those on the front
lines of human, animal and plant health to devise their
own solutions and generate accurate data for the global
community. For example, in 2010, the Danish Yellow Card
Initiative required farmers and veterinarians to track and
record on farm antibiotic use. The initiative complemented low-granularity sales data and helped respective
communities better understand what they were doing
and grow support for stewardship efforts.54 In LMICs,
enhancing national and local capacity to generate data
can have similar effects. Being able to produce and wield
robust surveillance data can increase the political weight
of LMIC concerns at the international level. OIE, WHO
and the UK Fleming Fund are already strengthening
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GAVI.8 Ultimately, the structural challenges posed by
AMR exceed the capabilities of any one nation. Overcoming the significant levels of inequality that have
hampered previous responses will depend on intensifying international collaboration, equitably pooling
resources and knowledge, and openly addressing the
global disparities driving infectious disease burdens
and the resulting need for antibiotics.
3. Tracked: Progress towards structural and equitable
antibiotic policies has to be tracked to ensure ongoing
effectiveness of interventions, promote integration of
international efforts and motivate sustained commitment of donors and funding recipients. While a regular independent international stocktake could help
ensure that policy interventions remain coordinated,
equitable and up to date,12 the metrics informing global decision making need to be reviewed and carefully
chosen.128 To avoid reifying existing inequalities and
HIC biosecurity concerns (see the Metrics section),
tracked policies should be based on and promote systems of contextual data gathering that are: multifactorial in their combination of existing and new metrics;
integrated in their pooling of knowledge from different One Health and regional contexts; and empowering by conferring agency to local communities.
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LIC usage and AMR surveillance capacity. However,
organisations still lack sufficient resources to sustainably
support laboratories and countries to enable them to
publish accurate country-
level data.29 New multifactorial and integrated metrics are also needed to produce
data that is meaningful in settings without formal health
and veterinary care systems. In the long term, reducing
reliance on decontextualised data gathering like traveller surveillance and restructuring reporting formats to
better reflect varying circumstances (see the Inequality
section) will significantly enhance the evidence base for
truly structural and equitable international antibiotic
policy-making.
CONCLUSION
The past eight decades have seen antibiotic policy-makers
struggle to overcome problematic metrics, narrow prioritisations, implementation deficits and global inequalities. The need for integrated architectures that act across
existing silos to push evidence into action on AMR is
being met through United Nations mandated mechanisms.10 To move beyond previous impasses, international policy will have to take seriously the infrastructural
dimensions of antibiotic use, provide equitable solutions
for communities across the globe and develop new forms
of tracking progress that are multifactorial, integrated
and empowering for the communities employing them.
Policies that take into account antibiotics’ SET have
the greatest potential to sustainably adapt the way the
global antibiotic commons are managed and accessed. As
highlighted in our ideal-type example of multifactorial
10

metrics and equitable capacity building in global food
production (figure 2), SET policies have the potential to
foster win-win situations for HIC and LMIC participants
alike.
If the ultimate goal of antibiotic policy is to reduce
mortality and morbidity resulting from treatable infections, then we need to adapt our food and health systems
to provide optimal access to effective antibiotic interventions when they are needed—and simultaneously reduce
the need for these interventions. This dual approach
requires polices that not only focus on ‘quick fixes’106
for existing systems and behavioural modifications at the
level of the individual. Instead, policies should consistently seek to adapt the wider physical and cultural infrastructures antibiotics are embedded in.
AMR is not a problem to be solved but a phenomenon
to be continuously managed. Individual policies may not
address all identified problem areas or integrate each of
our three intervention hallmarks. However, we believe
that our multidisciplinary SET of hallmarks can serve as
a compass to critically evaluate and improve antibiotic
policy in the present and for decades to come.
Author affiliations
1
School of History, University College Dublin, Dublin, Ireland
2
Oxford Martin School, University of Oxford, Oxford, UK
3
Department of Public Health and Policy/ Institute of Infection and Global Health,
University of Liverpool, Liverpool, UK
4
School of Social and Political Sciences, Faculty of Arts and Social Sciences, The
University of Sydney, Sydney, New South Wales, Australia
5
Princess Maha Chakri Sirindhorn Anthropology Center, Bangkok, Thailand
6
Antimicrobial Resistance and Veterinary Products Department, World Organisation
for Animal Health, Paris, Île-de-France, France

Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091

BMJ Glob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from http://gh.bmj.com/ on October 16, 2020 by guest. Protected by copyright.

Figure 2 An ideal-type set of interventions for international food production. Ideal-type example of how using reflective
policy-making in accordance with SET hallmarks could inform the design of equitable trade arrangements to: satisfy high
income country demand for affordable sustainably produced protein; fulfil low income country calls for structural healthcare
and surveillance capacity building and market access; encourage value driven. One health stewardship with multifactorial
metrics integrating data on animal health with low-cost environmental sentinel monitoring for antimicrobial residues as a proxy
for regional antimicrobial use (AMU). AMR, antimicrobial resistance; SET, Structural, Equitable and Tracked.

BMJ Global Health
Irisso, Paris-Dauphine University, PSL, INRAE, Paris, Île-de-France, France
Center for Disease Dynamics Economics and Policy, Washington, DC, USA
9
Department of Infectious Disease, Imperial College London, London, UK
10
Institute for Health and Society, Dept. of Community Medicine and Global Health,
University of Oslo, Oslo, Norway
11
Geography, College of Life and Environmental Sciences and Wellcome Centre for
Cultures and Environments of Health, University of Exeter, Exeter, UK
12
Global Strategy Lab, Dahdaleh Institute for Global Health Research, Faculty of
Health and Osgoode Hall Law School, York University, Toronto, Ontario, Canada
13
Institute for Science, Innovation and Society, School of Anthropology and Museum
Ethnography, University of Oxford, Oxford, UK
14
Infectious Diseases Research Collaboration, Kampala, Central Region, Uganda
15
School of Law, Social Innovation on Drug Program, Boston University, Boston,
Massachusetts, USA
16
Department of Global Health and Social Medicine, Harvard Medical School,
Boston, Massachusetts, USA
17
Department of Tropical Disease Biology, Liverpool School of Tropical Medicine,
Liverpool, UK
18
Pollution, UK Centre for Ecology & Hydrology, Wallingford, UK
19
Department of International Health, Johns Hopkins University Bloomberg School
of Public Health, Baltimore, Maryland, USA
20
Innovation + Design Enabling Access (IDEA) Initiative, ReAct - Action on Antibiotic
Resistance, Baltimore, Maryland, USA
21
Faculty of Social Sciences, Mahidol University, Salaya, Nakhon Pathom, Thailand
22
Global Coordination and Partnerships, AMR Division, World Health Organisation,
Geneva, Switzerland
23
Global Strategy Lab, York University, Toronto, Ontario, Canada
24
Department of Global Health and Development, London School of Hygiene &
Tropical Medicine, London, UK
8

Coalition, and as a Member of the Working Group on Antibiotic Resistance for the
President’s Council of Advisors on Science and Technology (2013–2014).
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement There are no data in this work.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits
others to copy, redistribute, remix, transform and build upon this work for any
purpose, provided the original work is properly cited, a link to the licence is given,
and indication of whether changes were made. See: https://creativecommons.org/
licenses/by/4.0/.
ORCID iDs
Claas Kirchhelle http://orcid.org/0000-0003-0910-8133
Isabel Frost http://orcid.org/0000-0002-0095-0845
Steven J Hoffman http://orcid.org/0000-0002-2064-3711
Adam P Roberts http://orcid.org/0000-0002-0760-3088
Clare I R Chandler http://orcid.org/0000-0001-6499-7522

REFERENCES

Twitter Claas Kirchhelle @Kirchhelle, Alex Broom @BroomAlex, Isabel Frost
@IsabelFrost19, Steven J Hoffman @shoffmania, Kevin Outterson @koutterson,
Adam P Roberts @anthroamr and Andrew C Singer @OxonAndrew
Acknowledgements We are grateful to all correspondents and participants of
the 2019 workshop for sharing their insights and expertise. The workshop and
activity for this manuscript was supported by the Antimicrobials in Society (AMIS)
programme (https://antimicrobialsinsociety.org/). The authors would like to thank
Charlotte Kirchhelle for her help in preparing the figures of this article.
Contributors CK and CC conceived the concept and cowrote this article with
contributions from PA, AB, KC, JPF, NF, IF, CG, SH, SJH, JL, SN, KO, SHP, SR, APR,
SRVK, ACS, ADS, LS, ET. CC acquired funding for the workshop and the articles.
Funding AMIS is funded by The Antimicrobial Resistance Cross Council Initiative
supported by the seven research councils in partnership with other funders.
The lead funders are the Economic and Social Research Council (ESRC) with the
Department of Health and the Arts and Humanities Research Council (AHRC).
Kirchhelle’s work was supported by a Wellcome Trust University Award at University
College Dublin and the Oxford Martin School. Fortané was supported by INRAE
(ANR-18-CE03-001), Frost by CDDEP, Nayiga by ESRC, Taylor by the UK Fleming
Fund. APR would like to acknowledge funding from the AMR Cross-Council
Initiative through a grant from the Medical Research Council, a Council of UK
Research and Innovation (Grant Number; MR/S004793/1)
Disclaimer The views expressed in this article are those of the authors and do not
necessarily reflect those of CIHR, the Government of Canada, or WHO.
Competing interests SH is Scientific Director of CIHR’s Institute of Population
and Public Health and CIHR’s Scientific Co-Lead for Antimicrobial Resistance. He
is Director of the WHO Collaborating Centre on Global Governance of Antimicrobial
Resistance. KO in principal investigator of CARB-X, a project at Boston University
(my employer), funded by three governments (US, UK and Germany) and two
charitable foundations (Wellcome Trust and the Bill & Melinda Gates Foundation).
CARB-X is a non-profit, making grants for preclinical antibacterial research. I
do not view this as a conflict, but disclose in an abundance of caution. APR is
the co-ordinator of the JPIAMR funded Network NEAR-AMR. ADS reports grants
from ReAct-Action on Antibiotic Resistance and from Open Society Foundation
during the conduct of the study. He served as Co-Convener of the UN Interagency
Coordination Group on Antimicrobial Resistance (2018–2019), as a member of
the Expert Commission on Addressing the Livestock Contribution to the Antibiotic
Resistance Crisis (2016–2017), as a commissioned author to the UK Commission
on AMR on 'A Framework for Costing the Lowering of Antimicrobial Use in Food
Animal Production' (2016), as Head of the Secretariat of the Antibiotic Resistance
Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091

1 Chandler CIR, Hutchinson E, Hutchison C. Addressing antimicrobial
resistance through social theory. An Anthropologically oriented
report. London: London School of Hygiene & Tropical Medicine,
2016.
2 Hoffman SJ, Caleo GM, Daulaire N, et al. Strategies for achieving
global collective action on antimicrobial resistance. Bull World
Health Organ 2015;93:867–76.
3 Hollis A, Maybarduk P. Antibiotic resistance is a tragedy of the
commons that necessitates global cooperation. J Law Med Ethics
2015;43 Suppl 3:33–7.
4 Cars O, Högberg LD, Murray M, et al. Meeting the challenge of
antibiotic resistance. BMJ 2008;337:a1438.
5 Laxminarayan R, Malani A. Extending the cure: policy responses to
the growing threat of antibiotic resistance: Earthscan, 2007.
6 Outterson K. The vanishing public domain: antibiotic resistance,
pharmaceutical innovation and intellectual property law. Lawreview
2005;67:67.
7 Hoffman SJ, Outterson K. Introduction: what will it take to address
the global threat of antibiotic resistance? J Law Med Ethics
2015;43 Suppl 3:6–11.
8 Rogers Van Katwyk S, Weldon I, Giubilini A, et al. Making use
of existing international legal mechanisms to manage the global
antimicrobial commons: identifying legal Hooks and institutional
mandates. Health Care Anal 2020;105. doi:10.1007/s10728-02000393-y. [Epub ahead of print: 31 Mar 2020].
9 Wernli D, Haustein T, Conly J, et al. A call for action: the application
of the International health regulations to the global threat of
antimicrobial resistance. PLoS Med 2011;8:e1001022.
10 IACG. No time to wait: securing the future from drug-resistant
infections. Report to the Secretar-General of the United nations.
New York: Interagency Coordination Group on Antimicrobial
Resistance, 2019.
11 WHO/OIE/FAO. Global action plan on antimicrobial resistance.
Geneva: World Health Organisation, 2015.
12 Van Katwyk SR, Balasegaram M, Boriello P, et al. A roadmap for
sustainably governing the global antimicrobial commons. Lancet
2019;394:1788–9.
13 Rogers Van Katwyk S, Grimshaw JM, Nkangu M, et al.
Government policy interventions to reduce human antimicrobial
use: a systematic review and evidence MAP. PLoS Med
2019;16:e1002819.
14 Kirchhelle C, Broom A, Chandler C, et al. The Informational
Deluge - A Review of 72 years of antibiotic evaluation, surveillance,
regulation, and calls to actionin preparation.
15 Tackling antimicrobial resistance 2019–2024. The UK’s five-year
national action plan. London Her Majesty’s Government, 2019.
16 WHO. Who global principles for the containment of antimicrobial
resistance in animals intended for food: report of a who
consultation with the participation of the food and agriculture
organization of the United nations and the office international des
Epizooties, Geneva, Switzerland 5-9 June 2000. World Health
Organization, 2000.
17 Hoffman SJ, Outterson K, Røttingen J-A, et al. An international
legal framework to address antimicrobial resistance: SciELO public
health, 2015.

11

BMJ Glob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from http://gh.bmj.com/ on October 16, 2020 by guest. Protected by copyright.

7

BMJ Global Health

12

44 Iroh Tam P-Y, Musicha P, Kawaza K, et al. Emerging resistance to
empiric antimicrobial regimens for pediatric bloodstream infections
in Malawi (1998-2017). Clin Infect Dis 2019;69:61–8.
45 Schnall J, Rajkhowa A, Ikuta K, et al. Surveillance and monitoring
of antimicrobial resistance: limitations and lessons from the gram
project. BMC Med 2019;17:176.
46 Aarestrup FM. Monitoring of antimicrobial resistance among food
animals: principles and limitations. J Vet Med B Infect Dis Vet
Public Health 2004;51:380–8.
47 Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic
consumption 2000 to 2010: an analysis of national pharmaceutical
sales data. Lancet Infect Dis 2014;14:742–50.
48 Van Boeckel TP, Pires J, Silvester R, et al. Global trends in
antimicrobial resistance in animals in low- and middle-income
countries. Science 2019;365:eaaw1944.
49 Giulieri SG, Tong SYC, Williamson DA. Using genomics to
understand meticillin- and vancomycin-resistant Staphylococcus
aureus infections. Microb Genom 2020;6:mgen000324.
50 Baker S, Thomson N, Weill F-X, et al. Genomic insights into
the emergence and spread of antimicrobial-resistant bacterial
pathogens. Science 2018;360:733–8.
51 Bennett RJ, Baker KS. Looking backward to move forward: the
utility of sequencing historical bacterial genomes. J Clin Microbiol
2019;57.
52 Barber M, Dutton AA, Beard MA, et al. Reversal of antibiotic
resistance in hospital staphylococcal infection. Br Med J
1960;1:11–17.
53 Kahn LH. One health and the politics of antimicrobial resistance
Baltimore. Johns Hopkins University Press, 2016.
54 FAO. Tackling antimicrobial use and resistance in pig production.
lessons learned in Denmark. Rome: Food and Agricultural
Organisation/ Ministry of Environment and Food of Denmark, 2019.
55 Sørum M, Johnsen PJ, Aasnes B, et al. Prevalence, persistence,
and molecular characterization of glycopeptide-resistant
enterococci in Norwegian poultry and poultry farmers 3 to
8 years after the ban on avoparcin. Appl Environ Microbiol
2006;72:516–21.
56 Walsh TR, Wu Y. China bans colistin as a feed additive for animals.
Lancet Infect Dis 2016;16:1102–3.
57 Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated
colistin resistance mechanism MCR-1 in animals and human
beings in China: a microbiological and molecular biological study.
Lancet Infect Dis 2016;16:161–8.
58 Shen Z, Wang Y, Shen Y, et al. Early emergence of mcr-1 in
Escherichia coli from food-producing animals. Lancet Infect Dis
2016;16:293.
59 WHO. Library of national action plans. Geneva: World Health
Organisation, 2020.
60 OIE. OIE list of antimicrobial agents of veterinary importance: world
organisation for animal health, 2019.
61 FAO/OIE/WHO. Second joint FAO/OIE/WHO expert workshop
on non-human antimicrobial usage and antimicrobial resistance:
management options. Oslo, Norway. Geneva: World Health
Organisation, 2004.
62 WHO. Executive summary. The selection and use of essential
medicines 2019. Report of the 22nd who expert Committee on the
selection and use of essential medicines. Geneva: World Health
Organisation, 2019.
63 Sharland M, Pulcini C, Harbarth S, et al. Classifying antibiotics in
the who essential medicines list for optimal use-be aware. Lancet
Infect Dis 2018;18:18–20.
64 Góchez D, Raicek M, Pinto Ferreira J, et al. OIE annual report on
antimicrobial agents intended for use in animals: methods used.
Front Vet Sci 2019;6:317.
65 WHO. Who methodology for a global programme on surveillance
of antimicrobial consumption. Geneva: World Health Organisation,
2016.
66 Queenan K, Chandler CIR, Goodman C. A review of methods
and metrics for studying human and livestock antibiotic use at the
granular level. London LSHTM, 2017.
67 Queenan K, Chandler CIR, Goodman C. Meeting report: metrics
and methods for assessing antibiotic use at the granular level in
humans and livestock in LMICs. London: LSHTM, 2017.
68 WHO. Global priority list of antibiotic-resistant bacteria to guide
research, discovery, and development of new antibiotics. Geneva:
World Health Organization, 2017.
69 OIE. Development and harmonisation of national antimicrobial
resistance surveillance and monitoring programmes for aquatic
animals. aquatic animal health code. Paris: World Organisation For
Animal Health, 2012.

Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091

BMJ Glob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from http://gh.bmj.com/ on October 16, 2020 by guest. Protected by copyright.

18 Kirk RGW. Recovering The Principles of Humane Experimental
Technique: The 3Rs and the Human Essence of Animal Research.
Sci Technol Human Values 2018;43:622–48.
19 So AD, Ruiz-Esparza Q, Gupta N, et al. 3Rs for innovating
novel antibiotics: sharing resources, risks, and rewards. BMJ
2012;344:e1782–4.
20 Bank W. Pulling together to beat superbugs. knowledge and
Implementaiton gaps in addressing antimicrobial resistance.
Washington DC: World Bank, 2019.
21 WHO. Turning plans into action for antimicrobial resistance (AMR).
Working paper 2.0: implementation and coordination. Geneva:
World Health Organization, 2019.
22 Dar OA, Hasan R, Schlundt J, et al. Exploring the evidence base
for national and regional policy interventions to combat resistance.
Lancet 2016;387:285–95.
23 Summers WC. Microbial drug resistance: a historical perspective.
Bacterial Resistance to Antimicrobials 2008;2:1–9.
24 Gradmann C. Magic bullets and moving targets: antibiotic
resistance and experimental chemotherapy, 1900-1940. Dynamis
2001;31:305–21.
25 Fortané N, Dispositif-Frontière LSC. La triple ontologie des
bactéries résistantes d’origine animale. Revue d'Anthropologie des
Connaissances 2015;9:265–90.
26 Gradmann C. Sensitive matters: the world health organisation
and antibiotic resistance testing, 1945-1975. Soc His Med
2013;26:555–74.
27 Drlica K, Perlin DS, Resistance A. Understanding and responding to
an emerging crisis. Upper Saddle River: Pearson Education, 2011.
28 WHO. WHONET software platform. Geneva: World Health
Organisation.
29 WHO. Global antimicrobial resistance surveillance system (glass)
report: early implementation 2017-2018. Geneva: WHO, 2019.
30 van der Bij AK, van Dijk K, Muilwijk J, et al. Clinical breakpoint
changes and their impact on surveillance of antimicrobial
resistance in Escherichia coli causing bacteraemia. Clin Microbiol
Infect 2012;18:E466–72.
31 Kassim A, Omuse G, Premji Z, et al. Comparison of clinical
laboratory Standards Institute and European Committee on
antimicrobial susceptibility testing guidelines for the interpretation
of antibiotic susceptibility at a university teaching hospital in
Nairobi, Kenya: a cross-sectional study. Ann Clin Microbiol
Antimicrob 2016;15:21.
32 Saha S, Saha S, Saha SK. Global science: barriers in Bangladesh.
Elife 2018;7:e41926.
33 Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial
resistance in bloodstream infection isolates at a large urban
hospital in Malawi (1998-2016): a surveillance study. Lancet Infect
Dis 2017;17:1042–52.
34 Kirchhelle C. Pyrrhic progress: antibiotics in Anglo-American food
production (1949-2018). New Brunswick: Rutgers University Press,
2020.
35 Hammerum AM, Heuer OE, Emborg H-D, et al. Danish integrated
antimicrobial resistance monitoring and research program. Emerg
Infect Dis 2007;13:1633–9.
36 Mölstad S, Löfmark S, Carlin K, et al. Lessons learnt during 20
years of the Swedish strategic programme against antibiotic
resistance. Bull World Health Organ 2017;95:764–73.
37 Tamura Y. The Japanese veterinary antimicrobial resistance
monitoring system (JVARM). OIE international standards on
Antimicrobial Resistance, 2003: 206–10.
38 OIE. OIE annual report on antimicrobial agents intended for use in
animals. better understanding of the global situation. third annual
report. Paris: World Organisation for Animal Health (OIE), 2018.
39 EMA. Trends in the sales of veterinary antimicrobal agents in
nine European countries. reporting period: 2005-2009. Brussels:
European Medicines Agency, 2011.
40 VMD. Uk veterinary antibiotic resistance and sales surveillance
report. UK-VARSS 2018. UK-VARSS new Haw veterinary medicines
Directorate, 2019.
41 Statens Serum Institut, NF Institute. DANMAP 2018 - Use of
antimicrobial agents and occurrence of antimicrobial resistance
in bacteria from food animals, food and humans in Denmark.
Copenhagen: Statens Serum Institut/ National Food Institute,
2019.
42 FDA. 2018 summary report on antimicrobials sold or distributed
for use in food-producing animals. Washington: Food and Drugs
Administration, 2019.
43 English Surveillance Programme for Antimicrobial Utilisation and
Resistance (ESPAUR). Report 2018-2019. London: Public Health
England, 2019.

BMJ Global Health

Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091

99 Podolsky SH. Historical perspective on the rise and fall and
rise of antibiotics and human weight gain. Ann Intern Med
2017;166:133–8.
100 Millar M. Inequality and antibiotic resistance: a contractualist
perspective. Bioethics 2019;33:749–55.
101 Poirot E, Skarbinski J, Sinclair D, et al. Mass drug administration for
malaria. Cochrane Database Syst Rev 2013;44.
102 Bogoch II, Utzinger J, Lo NC, et al. Antibacterial mass drug
administration for child mortality reduction: opportunities,
concerns, and possible next steps. PLoS Negl Trop Dis
2019;13:e0007315.
103 Keenan JD, Arzika AM, Maliki R, et al. Longer-Term assessment of
azithromycin for reducing childhood mortality in Africa. N Engl J
Med 2019;380:2207–14.
104 Romani L, Marks M, Sokana O, et al. Efficacy of mass drug
administration with ivermectin for control of scabies and impetigo,
with coadministration of azithromycin: a single-arm community
intervention trial. Lancet Infect Dis 2019;19:510–8.
105 Rid A, Littmann J, Buyx A. Evaluating the risks of public health
programs: rational antibiotic use and antimicrobial resistance.
Bioethics 2019;33:734–48.
106 Denyer Willis L, Chandler C. Quick fix for care, productivity, hygiene
and inequality: reframing the entrenched problem of antibiotic
overuse. BMJ Glob Health 2019;4:e001590.
107 Pearson M, Chandler C. Knowing antmicrobial resistance in
practice: a multi-country qualitative study with human and animal
healthcare professionals. Glob Health Action 2019;12:1599560.
108 Rochford C, Sridhar D, Woods N, et al. Global governance of
antimicrobial resistance. The Lancet 2018;391:1976–8.
109 UN. Paris agreement. New York: United Nations, 2016.
110 Rogers Van Katwyk S, Giubilini A, Kirchhelle C, et al. Exploring
models for an international legal agreement on the global
antimicrobial commons: lessons from climate agreements. Health
Care Anal 2020;387. doi:10.1007/s10728-019-00389-3. [Epub
ahead of print: 21 Jan 2020].
111 Clift C. Review of progress on antimicrobial resistance: background
and analysis. London: Chatham House: The Royal Institute of
International Affairs, 2019.
112 Ozawa S, Evans DR, Bessias S, et al. Prevalence and estimated
economic burden of substandard and Falsified medicines in lowand middle-income countries: a systematic review and meta-
analysis. JAMA Netw Open 2018;1:e181662.
113 Morgan DJ, Okeke IN, Laxminarayan R, et al. Non-Prescription
antimicrobial use worldwide: a systematic review. Lancet Infect Dis
2011;11:692–701.
114 Ahmad R, Zhu NJ, Leather AJM, et al. Strengthening strategic
management approaches to address antimicrobial resistance
in global human health: a scoping review. BMJ Glob Health
2019;4:e001730.
115 Pokharel S, Raut S, Adhikari B. Tackling antimicrobial resistance
in low-income and middle-income countries. BMJ Glob Health
2019;4:e002104.
116 Pokharel S, Adhikari B. Antimicrobial resistance and over the
counter use of drugs in Nepal. J Glob Health 2020;10:010360.
117 FAO/OIE/WHO. Monitoring global progress for addressing
antimicrobial resistance (AMR). analysis report of the second round
of results of AMR country self-assessment survey. Geneva: FAO/
OIE/ WHO, 2018.
118 Goutard FL, Bordier M, Calba C, et al. Antimicrobial policy
interventions in food animal production in South East Asia. BMJ
2017;358:j3544–41.
119 So AD, Shah TA, Roach S, et al. An integrated systems approach
is needed to ensure the sustainability of antibiotic effectiveness
for both humans and animals. J Law Med Ethics 2015;43 Suppl
3:38–45.
120 EU. MEPs back plans to halt spread of drug resistance from
animals to humans. Brussels: European Parliament, 2018.
121 Broom A, Kenny K, Kirby E, et al. Improvisation, therapeutic
brokerage and antibiotic (mis)use in India: a qualitative interview
study of Hyderabadi physicians and pharmacists. Crit Public Health
2020;30:16–27.
122 Broom J, Broom A, Kirby E. Context-Sensitive antibiotic
optimization: a qualitative interviews study of a remote Australian
hospital setting. J Hosp Infect 2018;100:265–9.
123 Hinchliffe S, Butcher A, Rahman MM. The AMR problem:
demanding economies, biological margins, and co-producing
alternative strategies. Palgrave Commun 2018;4.
124 Figuié M. Towards a global governance of risks: international health
organisations and the surveillance of emerging infectious diseases.
J Risk Res 2014;17:469–83.

13

BMJ Glob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from http://gh.bmj.com/ on October 16, 2020 by guest. Protected by copyright.

70 OIE. Harmonisation of national antimicrobial resistance surveillance
and monitoring programmes. Terrestial animal health code. Paris:
World Organisation for Animal health, 2018.
71 Savoldi A, Carrara E, Gladstone BP, et al. Gross national income
and antibiotic resistance in invasive isolates: analysis of the top-
ranked antibiotic-resistant bacteria on the 2017 who priority list. J
Antimicrob Chemother 2019;74:3619–25.
72 Pitzer VE, Meiring J, Martineau FP, et al. The invisible burden:
diagnosing and Combatting typhoid fever in Asia and Africa. Clin
Infect Dis 2019;69:S395–401.
73 So A, Sharma P. Tracking antimicrobial resistance in the
sustainable development goals, 2019. Available: http://sdg.iisd.org/
commentary/guest-articles/tracking-antimicrobial-resistance-in-
the-sustainable-development-goals/
74 Singer AC, Shaw H, Rhodes V, et al. Review of antimicrobial
resistance in the environment and its relevance to environmental
regulators. Front Microbiol 2016;7:7.
75 WHO. Critically important antimicrobials for human medicine - 5th
review. Geneva: WHO, 2017.
76 Podolsky SH. The evolving response to antibiotic resistance
(1945–2018). Palgrave Commun 2018;4.
77 Podolsky SH. The antibiotic era. reform, resistance and the pursuit
of a rational therapeutics. Baltimore: Johns Hopkins Press, 2015.
78 Gradmann C. Re-Inventing infectious disease: antibiotic resistance
and drug development at the Bayer company 1945-80. Med Hist
2016;60:155–80.
79 Schröter HG. Zwischen tradition und Fortschritt. AUS Der
Geschichte Der Pharmabereiche von Bayer, Hoechst und Schering
von 1935-1975. Frankfurter Historische Abhandlungen 2005;43.
80 Lie AK, Standards P. Producing Standards, producing the Nordic
region: antibiotic susceptibility testing, from 1950-1970. Sci
Context 2014;27:215–48.
81 Hobaek B, Lie AK. Less Is More: Norwegian Drug Regulation,
Antibiotic Policy, and the "Need Clause". Milbank Q
2019;97:762–95.
82 WHO. Who report on surveillance of antibiotic consumption. early
implementation 2016-2018. Geneva: WHO, 2018.
83 ECDC. Antimicrobial consumption in the EU/EEA. annual
epidemiological report for 2018. Brussels: European Centre for
Disease Control, 2019.
84 Krockow EM, Tarrant C. The International dimensions of
antimicrobial resistance: contextual factors shape distinct ethical
challenges in South Africa, Sri Lanka and the United Kingdom.
Bioethics 2019;33:756–65.
85 Kirchhelle C, Dyson ZA, Dougan G. A Biohistorical perspective
of typhoid and antimicrobial resistance. Clin Infect Dis
2019;69:S388–94.
86 Dyson ZA, Klemm EJ, Palmer S, et al. Antibiotic resistance and
typhoid. Clin Infect Dis 2019;68:S165–70.
87 Huang SS, Labus BJ, Samuel MC, et al. Antibiotic resistance
patterns of bacterial isolates from blood in San Francisco County,
California, 1996-1999. Emerg Infect Dis 2002;8:195–201.
88 Kirchhelle C. Pharming animals: a global history of antibiotics in
food production (1935–2017, 2018: 96.
89 Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival
of polymyxins for the management of multidrug-resistant gram-
negative bacterial infections. Clin Infect Dis 2005;40:1333–41.
90 Littmann J, Viens AM. The ethical significance of antimicrobial
resistance. Public Health Ethics 2015;8:phv025–24.
91 McMillen CW, Tuberculosis D, Global History A. To the present.
New Haven and London: Yale University Press, 2015: 1900.
92 Neville K, Bromberg A, Bromberg R, et al. The third epidemic-multidrug-resistant tuberculosis. Chest 1994;105:45–8.
93 Young DM, Harris HW, Charlebois ED, et al. An epidemic
of methicillin-resistant Staphylococcus aureus soft tissue
infections among medically underserved patients. Arch Surg
2004;139:947–53.
94 Doron A, Broom A. The spectre of Superbugs: waste, structural
violence and antimicrobial resistance in India. Worldwide Waste:
Journal of Interdisciplinary Studies 2019;2.
95 AAo S, Hindiyeh M, Sabateen AA. Embedding quality improvement
through a learning collaborative to reduce and sustain hospital-
acquired infections in the West bank. AMR Control, 2017: 96–8.
96 Davies M, Stockton B. Unseen enemy: doctors in Gaza. Bureau of
Investigative Journalism, 2018.
97 Singer AC, Colizza V, Schmitt H, et al. Assessing the ecotoxicologic
hazards of a pandemic influenza medical response. Environ Health
Perspect 2011;119:1084–90.
98 Rawson TM, Moore LSP, Castro-Sanchez E, et al. COVID-19
and the potential long-term impact on antimicrobial resistance. J
Antimicrob Chemother 2020;75:1681–4.

BMJ Global Health

14

146 Wellcome Trust News. Five pioneering ways to stop superbugs.
23.05.2019 ED. London, 2019.
147 Roope LSJ, Smith RD, Pouwels KB, et al. The challenge of
antimicrobial resistance: what economics can contribute. Science
2019;364:eaau4679.
148 Silbergeld EK. Chickenizing Farms & Food. How Industrial Meat
Production Endangers Workers, Animals, and Consumers.
Baltimore: Johns Hopkins University Press, 2016.
149 Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and
geographic convergence in antibiotic consumption between 2000
and 2015. Proc Natl Acad Sci U S A 2018;115:E3463–70.
150 Van Boeckel TP, Brower C, Gilbert M, et al. Global trends in
antimicrobial use in food animals. Proc Natl Acad Sci U S A
2015;112:5649–54.
151 Outterson K, Powers JH, Daniel GW, et al. Repairing the broken
market for antibiotic innovation. Health Aff 2015;34:277–85.
152 Outterson K. New business models for sustainable antibiotics.
London Chatham House - Royal Institute of International Affairs,
2014.
153 IACG. No time to wait: securing the future from drug-resistant
infections. New York Interagency coordination group on
antimicrobial resistance, 2019.
154 Reddy SG. Economics’ Biggest Success Story Is a Cautionary Tale.
Foreign Policy, 2019.
155 FAO/OIE/WHO. Monitoring and evaluation of the global action
plan on antimicrobial resistance. framework and recommended
indicators. Rome/ Paris/ Geneva: Food and Agricultural
Organisation/ World Organisation for Animal Health/ World Health
Organisation, 2019.
156 Gradmann C. From lighthouse to hothouse: Hospital hygiene,
antibiotics and the evolution of infectious disease, 1950-1990. Hist
Philos Life Sci 2017;40:8.
157 Kirchhelle C, Song S. Swann song: antibiotic regulation in British
livestock production (1953-2006). Bull Hist Med 2018;92:317–50.
158 Kirchhelle C. Between Bacteriology and Toxicology - Agricultural
Antibiotics and US Risk Regulation. In: Creager ANH, Gaudilliere
J-P, eds. Risk on the table. New York: Berghahn, 2021.
159 Jerolmack C. Who's worried about turkeys? How 'organisational
silos' impede zoonotic disease surveillance. Sociol Health Illn
2013;35:200–12.
160 Chien Y-J. How did international agencies perceive the avian
influenza problem? The adoption and manufacture of the
'One World, One Health' framework. Sociol Health Illn
2013;35:213–26.
161 Podolsky SH, Lie AK. Futures and their uses: antibiotics and
therapeutic revolutions. therapeutic revolutions: pharmaceuticals
and social change in the twentieth century. Chicago: University of
Chicago Press, 2016: 18–42.
162 Antimicrobials in Society [AMIS]. Social Science and AMR
Research Symposium - British Academy, London 2018. Available:
https://antimicrobialsinsociety.org/events/social-science-and-amr-
research-symposium/

Kirchhelle C, et al. BMJ Global Health 2020;5:e003091. doi:10.1136/bmjgh-2020-003091

BMJ Glob Health: first published as 10.1136/bmjgh-2020-003091 on 23 September 2020. Downloaded from http://gh.bmj.com/ on October 16, 2020 by guest. Protected by copyright.

125 Manton J, Gorsky M. Health planning in 1960s Africa: international
health organisations and the post-colonial state. Med Hist
2018;62:425–48.
126 Packard R. A history of global health: interventions into the lives of
other peoples. Baltimore: Johns Hopkins Press, 2016.
127 Singer AC, Kirchhelle C, Roberts AP. (Inter)nationalising the
antibiotic research and development pipeline. Lancet Infect Dis
2020;20:e54–62.
128 Adams V. Metrics: what counts in global health. Duke University
Press, 2016.
129 Bhutta ZA, Sommerfeld J, Lassi ZS, et al. Global burden,
distribution, and interventions for infectious diseases of poverty.
Infect Dis Poverty 2014;3:21.
130 WHO. Who Factsheet: drinking water. Geneva: World Health
Organisation, 2019.
131 WHO. Who Factsheet: sanitation. Geneva: World Health
Organisation, 2019.
132 OIE, WHO FAO. Technical brief on water, sanitation, hygiene
and wastewater management to prevent infections and reduce
the spread of AMR. Rome, Paris, Geneva: Food and Agriculture
Organization, World Organisation for Animal Health, World Health
Organization, 2020.
133 FAO. The Fao action plan on antimicrobial resistance 2016-2020.
Rome: FAO, 2016.
134 EU. A European one health action plan against antimicrobial
resistance (AMR). Brussels: European Union, 2017.
135 OIE. The OIE strategy on AMR and the prudent use of antibiotics.
Paris: World Organisation for Animal Health/ OIE, 2016.
136 Podolsky SH, Bud R, Gradmann C, et al. History teaches us that
confronting antibiotic resistance requires stronger global collective
action. J Law Med Ethics 2015;43 Suppl 3:27–32.
137 Glover RE, Dangoor M, Mays N. Educating patients or blaming
them? public education campaigns on antibiotic resistance. BMJ
Opinion 2019.
138 Commission E. Com (2011) 748 final communication from the
Commission to the European Parliament and Council – action plan
against the rising threats from antimicrobial resistance Brussels.
European Commission, 2011.
139 Indian Ministry of Environment FaCC. GSR 44 (E) Draft Notification.
The Gazette of India 2020 (No. 41 Part II - Section 3 - Sub-section
(i)), 2020: 1–11.
140 IFPMA. AMR Industry Alliance - 2020 Progress Report, 2020.
141 Gov.UK. Uk five year antimicrobial resistance strategy and action
plan 2013-2018, 2013.
142 FAO/WHO. Joint FAO/WHO meeting in collaboration with OIE on
foodborne antimicrobial resistance: role of the environment, crops
and biocides. microbiological risk assessment series. Rome, 2019.
143 EMA. Sales of veterinary antimicrobial agents in 31 European
countries in 2017. trends from 2010 to 2017 ninth ESVAC report.
Brussels: European Medicines Agency, 2019.
144 Nuffield Trust. Antibiotic prescribing UK. London; 2019.
145 FDA. Summary report on antimicrobials sold or distributed for
use in food-producing animals. Washington DC: Food and Drugs
Administration, 2018.

